Literature DB >> 20647805

Biomarkers as end points in clinical trials of severe sepsis: a garden of forking paths.

Jorge I F Salluh, Pedro Póvoa.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20647805     DOI: 10.1097/CCM.0b013e3181e941f6

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  5 in total

1.  Use of biomarkers in sepsis: many questions, few answers.

Authors:  Pedro Póvoa; Jorge Ibrain Figueira Salluh
Journal:  Rev Bras Ter Intensiva       Date:  2013-03

2.  Heme Causes Pain in Sickle Mice via Toll-Like Receptor 4-Mediated Reactive Oxygen Species- and Endoplasmic Reticulum Stress-Induced Glial Activation.

Authors:  Jianxun Lei; Jinny Paul; Ying Wang; Mihir Gupta; Derek Vang; Susan Thompson; Ritu Jha; Julia Nguyen; Yessenia Valverde; Yann Lamarre; Michael K Jones; Kalpna Gupta
Journal:  Antioxid Redox Signal       Date:  2020-08-24       Impact factor: 8.401

3.  Synthetic glycolipid-based TLR4 antagonists negatively regulate TRIF-dependent TLR4 signalling in human macrophages.

Authors:  Charys Palmer; Fabio A Facchini; Richard Po Jones; Frank Neumann; Francesco Peri; Grisha Pirianov
Journal:  Innate Immun       Date:  2021-04       Impact factor: 2.680

4.  Inflammasome-mediated GSDMD activation facilitates escape of Candida albicans from macrophages.

Authors:  Xionghui Ding; Hiroto Kambara; Rongxia Guo; Apurva Kanneganti; Maikel Acosta-Zaldívar; Jiajia Li; Fei Liu; Ting Bei; Wanjun Qi; Xuemei Xie; Wenli Han; Ningning Liu; Cunling Zhang; Xiaoyu Zhang; Hongbo Yu; Li Zhao; Fengxia Ma; Julia R Köhler; Hongbo R Luo
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

5.  The synthetic glycolipid-based TLR4 antagonist FP7 negatively regulates in vitro and in vivo haematopoietic and non-haematopoietic vascular TLR4 signalling.

Authors:  Charys Palmer; Francesco Peri; Frank Neumann; Feroz Ahmad; David S Leake; Grisha Pirianov
Journal:  Innate Immun       Date:  2018-09-12       Impact factor: 2.680

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.